Targeted therapies: The toxic reality of new drugs

Nature Reviews Clinical Oncology

Volumn 9, Issue 9, 2012, Pages 488-

  Kirk, Rebecca ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; AROMATASE INHIBITOR; NEW DRUG; TAMOXIFEN;

BREAST CANCER; CANCER PATIENT; DRUG EFFICACY; DRUG FATALITY; DRUG RESEARCH; DRUG SAFETY; DRUG TOLERABILITY; FOOD AND DRUG ADMINISTRATION; HUMAN; META ANALYSIS (TOPIC); NOTE; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK BENEFIT ANALYSIS; TOXICITY TESTING; UNSPECIFIED SIDE EFFECT;

EID: 84865687710     PISSN: 17594774     EISSN: 17594782     Source Type: Journal    
DOI: 10.1038/nrclinonc.2012.134     Document Type: Note

References (1)

1. Original article Niraula, S. et al. The price we pay for progress: a meta-analysis of harms and newly approved anticancer drugs. J. Clin. Oncol. doi:10-1200/JCO.2011-40.3824